Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CE119
- Development stage
- Preclinical
- Lead developer
- Cello Therapeutics
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
CE119 is a preclinical-stage small molecule chemotherapy agent being developed by Cello Therapeutics. It is formulated using the company's proprietary Cellular Nanoparticle (CNP) platform technology, which involves coating drug payloads with natural cellular membranes to create biomimetic nanoparticles. This delivery system is designed to improve the targeted delivery of chemotherapy agents to tumor sites, potentially enhancing efficacy while reducing systemic toxicity. CE119 is currently under investigation for the treatment of colorectal cancer.
Beyond the preview
Go deeper on CE119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CE119.